Fig. 5.

Scenario 2: model-predicted maximum renal excretion of uric acid at steady state and maximal sUA reduction percentage change from baseline at various verinurad (ER8 formulation) and XOI (febuxostat) treatment combinations. Simulation with variability (see “Methods” section for details). Combination doses refer to (verinurad dose, febuxostat dose). Datapoints and error bars correspond to median and 5th and 95th quantile (simulation included 500 subjects); grey area corresponds to the 5th and 95th quantile of the baseline. Simulations were performed assuming following baseline characteristics: eGFR = 60 mL/min/1.73 m²; baseline sUA = 8.5 mg/dL; baseline FEUA = 7.7%; non-Asian; verinurad ER8 formulation given in fed state. eGFR estimated glomerular filtration rate, ER8 extended release formulation, FEUA fractional excretion of uric acid, sUA serum uric acid